Home
About
Overview
Sharing Data
ORCID
Help
History (7)
Extensive double humanization of both liver and hematopoiesis in FRGN mice.
Towards spoken clinical-question answering: evaluating and adapting automatic speech-recognition systems for spoken clinical questions.
Women in Science and Health Achievement Award
PETS-D: Impact on Diabetes Management Outcomes.
Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
See All 7 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Jarvis CI, Cabrera A, Charron D. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann Pharmacother. 2013 Nov; 47(11):1532-9.
View in:
PubMed
subject areas
Blood Glucose
Clinical Trials as Topic
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Dose-Response Relationship, Drug
Drug Therapy, Combination
Humans
Hypoglycemic Agents
Piperidines
Treatment Outcome
Uracil